A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy

PharmacoEconomics

Volumn 19, Issue 9, 2001, Pages 955-967

  Dranitsaris, G ^a,b   Leung, P ^a   Ciotti, R ^c   Ortega, A ^d   Spinthouri, M ^e   Liaropoulos, L ^e   Labianca, R ^f   Quadri, A ^f  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c Servizio di Riani Mazione   (Italy)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e UNIVERSITY OF ATHENS   (Greece)

^f Ospedali Reuniti di Bergamo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; CISPLATIN; NEUROKININ 1 RECEPTOR ANTAGONIST; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; CANADA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CULTURAL FACTOR; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; FEMALE; GREECE; HEALTH CARE COST; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIOECONOMICS; SPAIN;

EID: 0034796671     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119090-00007     Document Type: Article

References (26)

1. Quality of life consequences of chemotherapy-induced emesis
2. Cancer of the breast
3. Standard treatment of chemotherapy-induced emesis
4. Serotonin antagonists: A new class of antiemetic agents
5. Pharmacology and antiemetic properties of ondansetron
6. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting
7. 3 (serotonin) antagonist-ondansetron (GR38032F) with high dose metoclopramide in the control of cisplatin-induced emesis
8. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomised, parallel-group study
9. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy
10. Dexamethasone improves the efficacy of granisetron in the first 24 hours following high dose cisplatin chemotherapy
11. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy
12. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy
13. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis
14. Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antonist in ferrets
15. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040
16. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis
17. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist
18. Using willingness-to-pay as a measure of benefits
19. When do the 'Dollars' make sense? Toward a conceptual framework for contingent valuation studies in health care
20. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: An assessment of amifostine cytoprotection
21. What are cancer patients willing to pay for epoetin alfa: A cost-benefit analysis
22. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis
23. A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin
24. Identification and assessment of prognostic factors
25. Economic evaluation of insulin humalog versus neutral insulin therapy using a willingness to pay approach